The prognostic significance of the neutrophil-to-lymphocyte ratio and the platelet-to-lymphocyte ratio in giant cell tumor of the extremities

Table 1 Association of the patients’ clinical parameters with NLR and PLR

clinical parameters	total	NLR		p-value	PLR		p-value
clinical parameters	total	LNLR (n = 113)	HNLR (n = 50)	p-value	LPLR (n = 90)	HPLR (n = 73)	p-value
age (year)	38.49 ± 11.10	38.29 ± 11.18	38.94 ± 11.03	0.732	39.07 ± 10.48	37.78 ± 11.86	0.464
Sex
Male	91	63	28	0.977	49	42	0.693
Female	72	50	22		41	31
Companacci stage
I-II stage	86	70	16	< 0.001	59	27	< 0.001
III stage	77	43	34		31	46
tumor diameter (cm)	5 (4~7)	5 (4~6)	6 (5~8)	0.048	5 (4~6)	6 (5~8)	0.006
ALP(U/L)	79 (63~122)	76 (62~121)	98 (64~136)	0.047	73 (59~107)	91 (68~124)	0.008
white blood cell (10⁹/L)	6.03 (5.12~7.06)	6.01 (5.13~6.79)	6.20 (5.04~7.30)	0.450	5.95 (5.05~7.06)	6.20 (5.15~7.04)	0.544
neutrophil (%)	55.4 (50.0~61.6)	52.6 (47.8~56.2)	63.6 (61.4~68.4	< 0.001	54.6 (48.8~60.7)	57.1 (50.6~63.2)	0.120
lymphocytes(%)	29.5 (24.2~36.6)	33.8 (29.2~38.9)	22.2 (18.9~24.3)	< 0.001	31.1 (25.6~37.1)	28.2 (23.8~34.2)	0.117
platelet (10⁹/L)	232 (195~272)	231 (191~266)	246 (200~290)	0.159	203 (165~235)	274 (242~314)	< 0.001
ESR (mm/h)	17 (9~34)	16 (9~34)	19 (10~36)	0.439	16 (8~37)	21 (10~34)	0.471
CRP (mg/L)	8.16 (3.77~13.57)	7.64 (3.65~11.93)	12.51 (4.05~23.38)	0.043	6.52 (3.44~11.89)	10.59 (4.39~25.85)	0.005

ALP, alkaline phosphatase; ESR, erythrocyte sedimentation rate; CRP, C-reactive protein; NLR, neutrophil-to-lymphocyte ratio; PLR, platelet-to-lymphocyte ratio

ISSN: 1471-2407